324 related articles for article (PubMed ID: 19278968)
21. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.
Oudin C; Chevallier P; Furst S; Guillaume T; El Cheikh J; Delaunay J; Castagna L; Faucher C; Granata A; Devillier R; Chabannon C; Esterni B; Vey N; Mohty M; Blaise D
Haematologica; 2014 Nov; 99(11):1762-8. PubMed ID: 25085356
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
23. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study.
Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q
Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation.
Yakoub-Agha I; de La Salmonière P; Ribaud P; Sutton L; Wattel E; Kuentz M; Jouet JP; Marit G; Milpied N; Deconinck E; Gratecos N; Leporrier M; Chabbert I; Caillot D; Damaj G; Dauriac C; Dreyfus F; François S; Molina L; Tanguy ML; Chevret S; Gluckman E
J Clin Oncol; 2000 Mar; 18(5):963-71. PubMed ID: 10694545
[TBL] [Abstract][Full Text] [Related]
25. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
26. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.
Schmid C; de Wreede LC; van Biezen A; Finke J; Ehninger G; Ganser A; Volin L; Niederwieser D; Beelen D; Alessandrino P; Kanz L; Schleuning M; Passweg J; Veelken H; Maertens J; Cornelissen JJ; Blaise D; Gramatzki M; Milpied N; Yakoub-Agha I; Mufti G; Rovira M; Arnold R; de Witte T; Robin M; Kröger N
Haematologica; 2018 Feb; 103(2):237-245. PubMed ID: 29101205
[TBL] [Abstract][Full Text] [Related]
27. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.
Kim SY; Le Rademacher J; Antin JH; Anderlini P; Ayas M; Battiwalla M; Carreras J; Kurtzberg J; Nakamura R; Eapen M; Deeg HJ
Haematologica; 2014 Dec; 99(12):1868-75. PubMed ID: 25107891
[TBL] [Abstract][Full Text] [Related]
29. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
30. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Drozd-Sokołowska J; Karakulska-Prystupiuk E; Biecek P; Kobylińska K; Piekarska A; Dutka M; Waszczuk-Gajda A; Mądry K; Kopińska A; Gołos A; Góra-Tybor J; Szwedyk P; Bołkun Ł; Czyż A; Giebel S; Basak GW; Dwilewicz-Trojaczek J
Eur J Haematol; 2021 Jul; 107(1):129-136. PubMed ID: 33764578
[TBL] [Abstract][Full Text] [Related]
31. T-cell receptor excision circle levels after allogeneic stem cell transplantation are predictive of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome.
Uzunel M; Sairafi D; Remberger M; Mattsson J; Uhlin M
Stem Cells Dev; 2014 Jul; 23(14):1559-67. PubMed ID: 24617310
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
34. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
35. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
[TBL] [Abstract][Full Text] [Related]
36. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
37. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy.
Anderson JE; Gooley TA; Schoch G; Anasetti C; Bensinger WI; Clift RA; Hansen JA; Sanders JE; Storb R; Appelbaum FR
Blood; 1997 Apr; 89(7):2578-85. PubMed ID: 9116305
[TBL] [Abstract][Full Text] [Related]
38. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
[TBL] [Abstract][Full Text] [Related]
40. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
de Lima M; Anagnostopoulos A; Munsell M; Shahjahan M; Ueno N; Ippoliti C; Andersson BS; Gajewski J; Couriel D; Cortes J; Donato M; Neumann J; Champlin R; Giralt S
Blood; 2004 Aug; 104(3):865-72. PubMed ID: 15090449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
